Pauline Anderson

July 14, 2026 LONDON — Blood-based biomarker (BBM) testing may enable primary care physicians (PCPs) to diagnose Alzheimer's disease (AD) as

Long-term exposure to outdoor heat was associated with lower amyloid-beta42/40 and higher p-tau181 levels in older women, but not men, suggesting heat may influence early AD-related pathology.

July 15, 2026 LONDON — Long-term exposure to outdoor heat was associated with a blood biomarker profile consistent with early Alzheimer's Disease (AD) pathology — but only in women — preliminary research suggests.

February 15, 2022 We and our partners process data to provide: List of Partners (vendors)

A $100 million global trial will investigate whether adding a metabolism-targeting therapy to multidomain lifestyle intervention further reduces the risk of cognitive decline in older adults at risk for dementia.

July 21, 2026 LONDON — A global trial will evaluate whether adding a metabolism-targeting therapy to intensive lifestyle intervention can

July 23, 2026 LONDON — A post hoc analysis of a phase 3 trial suggested the lipid-lowering drug obicetrapib may have its greatest effect on

The lipid-lowering drug obicetrapib produces the greatest reductions in the Alzheimer’s biomarker p-tau217 among APOE4 carriers, providing the rationale for a planned Alzheimer’s prevention trial.

July 24, 2026 JAMA Neurol. 2026; doi:10.1001/jamaneurol.2026.2262

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.